Emergent Biosolutions EBS Deferred Revenue
Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by Emergent Biosolutions in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityCurrent.
The official record: Emergent Biosolutions’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Emergent Biosolutions's deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Emergent Biosolutions's deferred revenue?
- Emergent Biosolutions (EBS) reported deferred revenue of $12.2M in Q1 2026.
- How has Emergent Biosolutions's deferred revenue changed year-over-year?
- Emergent Biosolutions's deferred revenue increased by 171.1% year-over-year, from $4.5M to $12.2M.
- What is the long-term trend for Emergent Biosolutions's deferred revenue?
- Over 5 years (2020 to 2025), Emergent Biosolutions's deferred revenue has grown at a -35.4% compound annual growth rate (CAGR), from $44.6M to $5M.
- What does deferred revenue mean?
- Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.